The majority of patients with pancreatic cancer who undergo curative resection experience rapid disease recurrence. In previous small studies, high expression of the mismatch-repair protein mutL protein homolog 1 (MLH1) in pancreatic cancers was associated with better outcomes. The objective of this study was to validate the association between MLH1 expression and survival in patients who underwent resection of pancreatic cancer and received adjuvant chemoradiation. METHODS: Samples were obtained from the NRG Oncology Radiation Therapy Oncology Group 9704 prospective, randomized trial (clinicaltrials.gov identifier NCT00003216), which compared 2 adjuvant protocols in patients with pancreatic cancer who underwent resection. Tissue microarrays were prepared from formalin-fixed, paraffin-embedded, resected tumor tissues. MLH1 expression was quantified using fluorescence immunohistochemistry and automated quantitative analysis, and expression was dichotomized above and below the median value. RESULTS: Immunohistochemical staining was successfully performed on 117 patients for MLH1 (60 and 57 patients from the 2 arms). The characteristics of the participants who had tissue samples available were similar to those of the trial population as a whole. At the time of analysis, 84% of participants had died, with a median survival of 17 months. Elevated MLH1 expression levels in tumor nuclei were significantly correlated with longer disease-free and overall survival in each arm individually and in both arms combined. Two-year overall survival was 16% in patients who had low MLH1 expression levels and 53% in those who had high MLH1 expression levels (P <.0001 for both arms combined). This association remained true on a multivariate analysis that allowed for lymph node status (hazard ratio, 0.41; 95% confidence interval, 0.27-0.63; P <.0001). CONCLUSIONS: In the current sample, MLH1 expression was correlated with longterm survival. Further studies should assess whether MLH1 expression predicts which patients with localized pancreatic cancer may benefit most from aggressive, multimodality treatment. Cancer 2018;124:491-8.
INTRODUCTION
Over 48,000 individuals are diagnosed with pancreatic cancer each year in the United States, and overall 5-year survival is 7%. 1 At diagnosis, approximately 20% have resectable disease; however, even among these patients, the median survival is only 15 months because of the early development of regional and metastatic disease. 2 There is an unmet need for the upfront identification of the subset of patients who demonstrate prolonged survival and derive benefit from such an aggressive approach.
Adjuvant chemotherapy is the standard of care for patients with resected pancreatic cancer. 3 Additional adjuvant options include radiation therapy (RT) to the tumor bed and regional lymphatic drainage. 4 The NRG Oncology-Radiation Therapy Oncology Group (RTOG) 9704 study was a randomized, phase 3 clinical trial comparing 2 different adjuvant protocols in patients with grossly resected pancreatic adenocarcinoma. 5 All patients received concurrent 5-fluorouracil (5-FU) plus RT; in addition, the control arm received 5-FU before and after RT, whereas the experimental arm received gemcitabine. Five-year overall survival (OS) was 18% and 22% in the 5-FU and gemcitabine arms, respectively (not significant). 6 On multivariate analysis, patients in the gemcitabine arm who had tumors of the pancreatic head experienced a trend toward improved OS (P 5 .08).
The DNA-mismatch repair (MMR) pathway corrects base substitution and insertion-deletion errors. 7 MMR dysfunction leads to the cellular acquisition of both point mutations and the instability of long, repetitive DNA sequences (ie, microsatellite instability [MSI] ). Inherited MMR dysfunction is associated with increased rates of carcinogenesis (hereditary nonpolyposis colon cancer or Lynch syndrome). 8 The MMR machinery has an additional function of sensing DNA lesions, triggering cell-cycle checkpoints and apoptosis. 9 MutL protein homolog 1 (MLH1) is a pivotal member of the MMR pathway, and complete loss of MLH1 is the most common cause of MSI. 10 Germline mutations in MLH1 are rare in pancreatic cancer, with an estimated frequency of <1%.
11 Likewise, wholegenome sequencing has demonstrated that structural somatic mutations in MLH1 are rare (approximately 2%); however, single allelic loss is observed in approximately 9% of tumors. 12 Whole-exome sequencing of 15 pancreatic cancer-derived cell lines revealed that the expression of MLH1 protein was decreased in cells that had MLH1 allelic loss. 13 Cells that were haplodeficient for MLH1 had decreased MLH1 expression and an increased number of indel mutations; however, they nonetheless tested negative on a polymerase chain reaction-based MSI assay. Thus, it appears that even a relative decrease in MLH1 expression may impair DNA fidelity without inducing MSI.
The clinical significance of decreased MLH1 expression in the absence of MSI is unknown; 1 small, retrospective series indicated that elevated MLH1 expression was significantly associated with favorable differentiation, fewer lymph node metastases, and improved OS.
14 In another study, increased MLH1 was associated with high tumor differentiation, fewer lymph node metastases, and tumor location. 15 In the current study, we hypothesized that resected pancreatic tumors with decreased MLH1 expression would demonstrate impaired MMR function and resistance to adjuvant chemoradiation, influencing OS.
MATERIALS AND METHODS
Inclusion criteria for NRG Oncology RTOG 9704 included patients with nonmetastatic, histologically confirmed pancreatic adenocarcinoma who had undergone gross total tumor resection. Patients with poor performance status, inadequate organ function, or previous cytotoxic treatments were excluded. Protocol therapy was required to begin 3 to 8 weeks after resection.
Specimen and Biomarker Analysis
Tissue microarrays (TMAs) with 0.6-mm cores were prepared from standard paraffin blocks of tissue that was removed during surgery (ie, before the delivery of systemic therapy). MLH1 was detected using a primary monoclonal antibody (clone EPR3894; Epitomics, Burlingame, CA) and was observed using the EnVision 1 system (K4011; DAKO, Carpenteria, CA). Pan-cytokeratin was detected with polyclonal antibody (BP5069; Acris, San Diego, CA) and was observed with Alexa-555-conjugated secondary antibody (A21435; Life Technologies, Burlington, ON, Canada).
Automated image acquisition was performed using the HistoRx PM-2000 imaging platform (HistoRx Inc, Branford, CT), and digital images were analyzed using the HistoRx AQUAnalysis program (version 2.3.4.1; HistoRx Inc), as previouslydescribed. 16, 17 Briefly, highresolution digital images were obtained for each TMA core using separate filters to define the nuclear (4 0 ,6-diamidino-2-phenylindole dihydrochloride [DAPI]), tumor (indocarbocyanine [Cy3]), and MLH1 (indodicarbocyanine [Cy5]) compartments. An analysis algorithm was constructed to generate a tumor-specific mask by thresholding the pan-cytokeratin images, and the tumor nuclear compartment was created by isolating DAPI-positive tumor nuclei within that area. The nuclear automated quantitative analysis (AQUA) score (nAQUA) (Supporting Fig. 1 ; see online supporting information), representing MLH1 expression, was defined as the average Cy5 pixel intensity within the tumor nuclear area for each TMA core.
Unusable areas were removed before each image was processed using optimized threshold values. Images were validated according to the following: 1) > 10% of the tissue area was pan-cytokeratin positive, 2) > 50% of the image was usable (ie, there was no overlapping or out-offocus tissue), and 3) the thresholding produced accurate masked areas. An example of the staining for MLH1 is presented in Supporting Figure 1 (see online supporting information). Of note, immunohistochemical staining Original Article and scoring were performed on blinded, nonannotated specimens.
Statistical Methods
MLH1 expression data were forwarded to the RTOG central office, where the samples were matched with clinical outcomes and a survival analysis was performed. Failure for OS was defined as death from any cause and was measured from the date of randomization to the date of death or of last follow-up for censored patients. Failure for disease-free survival (DFS) was defined as local, regional, or distant relapse; the appearance of a second primary lesion; or death from any cause and was measured from the date of randomization to the date of first failure or last follow-up for censored patients. The following baseline characteristics were dichotomized: pathologic tumor (T)-classification (T1 and T2 vs T3 and T4) and American Joint Committee on Cancer stage (I and II vs III and IV). Race was categorized as white versus African American/ other. Statistical comparisons to assess potential associations between baseline characteristics and MLH1 grouping were carried out using the chi-square test or the Fisher exact test. OS and DFS were estimated univariately with the Kaplan-Meier method, 18 and MLH1 groups were compared using the log-rank test. 19 The reported median survival and DFS are the times (in years) at which 50% of the patients had failed.
Antibody staining for MLH1 expression was analyzed as a continuous variable and as a categorical variable using the median level for all patients as a cutoff point (below the median [<median] vs at or above the median [median]). Univariate and multivariate Cox proportional-hazards models 20 were used to determine whether there were any associations between MLH1 expression and survival (OS and DFS). The first level in the MLH1 grouping (<median) was used as the reference level. A hazard ratio (HR) > 1.00 indicated an increased risk of failure for patients who had median versus < median MLH1 expression. For the multivariate analysis, only the MLH1 grouping was forced into the models, and a stepwise selection procedure was used to choose other variables using a 5 .05 as the entry and exit criteria for the model building. The following variables were assessed in the models along with MLH1 expression: treatment arm, age, sex, race, tumor location, lymph node status, greatest tumor dimension, and surgical margin status. All analyses were performed on all patients and then within each treatment arm.
To adjust for the multiple comparisons in this exploratory analysis, a 2-sided P value < .01 was considered statistically significant. P values .01 and <.05 were considered to indicate a trend toward statistical significance. All analyses were performed using SAS/ STAT software (version 9.4; SAS Institute Inc, Cary, NC).
The analysis was performed on tissue collected in the setting of a prospective clinical trial sponsored by the National Institutes of Health. The trial was performed with the approval of each medical center's institutional review board, in accordance with an assurance filed with and approved by the US Department of Health and Human Services; in addition, each participant provided informed consent.
RESULTS
In total, 538 patients were enrolled on the trial, and tissue was available for 220 patients, of whom MLH1 expression was quantifiable in 131 patients. MLH1 expression could not be quantified for 74 patients because of the low quantity/quality of tumor in the core and, for 15 patients, because of variations in immunohistochemical staining for pan-cytokeratin and DAPI. Fourteen patients were excluded from this analysis because they did not meet eligibility requirements for NRG Oncology-RTOG 9704. Thus, there were 117 eligible and analyzable patients. Table 1 provides baseline characteristics. There were no statistically significant associations observed between pretreatment characteristics and MLH1 nuclear expression, nor were there significant differences in OS or DFS between patients who could and could not be analyzed (Supporting Table 1 ; see online supporting information). Supporting Table 2 (see online supporting information) provides a follow-up and outcomes summary for the 117 patients by treatment arm and for the entire study. The median follow-up for surviving patients was 7 years in each arm (range, 2-9 years). For all 117 patients, the median expression of MLH1 in tumor nuclei was 3636.1 (range, 408-6321).
Increased expression of MLH1 in tumor nuclei was associated with longer OS and DFS in both treatment arms (5-FU: OS, 9% vs 33% 4-year survival; P < .005; gemcitabine: OS, 8% vs 33% 4-year survival; P < .005). Because MLH1 expression was similarly predictive in both arms, and overall outcomes in the 2 arms were very similar, the arms were combined in subsequent analyses. The 4-year OS rate for patients who had MLH1 nuclear expression < median versus median was 9% (95% confidence interval [CI], 3%-18%) and 33% (95% CI, 22%-45%), respectively (P < .0001; log-rank test) ( Table 2 , Fig. 2 ). On univariate Cox analysis, patients who had MLH1 nuclear expression median had a 57% decrease in the risk of dying compared with those who had MLH1 nuclear expression < median (HR, 0.43; 95% CI, 0.28, 0.64; P < .0001). Similarly, the 4-year DFS rate for patients who had MLH1 nuclear expression < median versus median was 2% (95% CI, 0%-1%) and 18% (95% CI, 9%-29%), respectively (P 5 .0002; log-rank test) (Supporting Fig. 2 ; see online supporting information). Patients who had tumors with high MLH1 expression had a 51% decrease in the risk of failing than those who had tumors with low MLH1 nuclear expression (HR, 0.49; 95% CI-0.33, 0.72; P 5 .0003). When MLH1 expression in tumor nuclei was analyzed as a continuous variable, a 500-unit increase in MLH1 nuclear expression corresponded to an 11%/10% reduction in the risk of dying/failing (OS: HR, 0.89; 95% CI, 0.81-0.98; P 5 .013; DFS: HR, 0.90; 95% CI, 0.83-0.98; P 5 .017).
The multivariate Cox proportional-hazards models for OS are provided in Table 3 . After adjusting for lymph node status, a 500-unit increase in MLH1 nuclear expression was associated with a 12% decrease in the risk of dying (HR, 0.88; 95% CI, 0.80-0.96; P 5 .0045). Likewise, after adjusting for lymph node status, patients who had MLH1 nuclear expression median were associated with a 59% reduction in the risk of dying compared with patients who had MLH1 nuclear expression < median (HR, 0.41; 95% CI, 0.27-0.63; P < .0001). In the multivariate Cox proportional-hazards models for DFS, only MLH1 nuclear expression had a statistically significant association with DFS; no other variables were added to the models (results not shown).
DISCUSSION
This study has demonstrated that higher MLH1 expression in tumor cell nuclei correlates with improved OS in patients with resected pancreatic cancer who receive adjuvant chemoradiation, with an HR of 0.41 on multivariate analysis. Furthermore, the Kaplan-Meier survival curves start to separate at year 1 and then stay apart (Fig. 2) , suggesting that MLH1 expression predicts long-term outcomes. These findings are in keeping with the hypothesis that tumors with low MLH1 expression may have impaired MMR function and, consequently, demonstrate treatment resistance.
Function and Expression of MLH1
The MLH1 gene is a pivotal member of the MMR pathway. MLH1 presence/function may be assessed on the genetic, protein, or functional level. Structural mutations within the MLH1 gene are rare events in pancreatic cancer (<1% of sporadic cancers), although single allelic loss is more frequent. 12 Multiple factors that impact MLH1 expression include copy number, allelic loss, 13 promoter hypermethylation, 15 histone acetylation, 21 and microRNA expression.
14 On the molecular level, the transcription factor Original Article GLI1 (human glioma-associated oncogene homolog 1), which is associated with the hedgehog signaling pathway, decreases MLH1 expression and consequent MMR activity. 22 In addition, it has been observed that external factors, such as hypoxia, 23 exposure to chemotherapy, 24 and epigenetic modifiers, 23, 25 influence MLH1 expression levels.
Few investigators have examined the clinical significance of MLH1 expression in pancreatic cancer. In agreement with the current results, 2 small Chinese studies noted that increased MLH1 expression, as assessed by manual pathologist grading, was associated with good prognostic factors and possibly survival, 14, 15 although another small study challenged those findings. 26 These studies were limited by their lack of clinical details and the diverse methods used to quantify MLH1 expression. Single nucleotide polymorphisms (SNPs) within MMR genes correlate with various outcomes in pancreatic cancer, including the response to chemoradiation and OS 27 ; however, it is unclear how the presence of these SNPs relates to gene expression or MMR function. Conversely, Japanese investigators noted that cancers with a high frequency of MSI were associated with a better prognosis 28, 29 ; however the incidence of MSI in those studies was an order of magnitude greater than that noted in North America and Europe, raising questions regarding the generalizability of the findings.
MLH1, MSI, and Response to DNA-Damaging Agents
MSI is considered a functional demonstration of MMR dysfunction. MSI may be caused by germline, somatic, or epigenetic silencing of 1 of several MMR genes, including MLH1, MSH2, MSH6, and PMS2. The incidence of MSI in pancreatic cancer is much higher in Japan (approximately 15% 29 than in North America and Europe (approximately 1% 30 . However MSI is an imperfect measure of MMR function: heterozygous loss of MLH1 is associated with decreased MLH1 expression and increased frequency of indel DNA mutations, but not with classic MSI. 13 Tumors with dysfunctional DNA repair are generally considered sensitive to DNA-damaging agents. 31 Although the MMR pathway is concerned with DNA repair, paradoxically, MMR dysfunction in the preclinical setting has repeatedly been associated with primary resistance to cytotoxic therapies, including methylating agents, 6-thioguanine, cisplatin, carboplatin, temozolomide, and etoposide. 32, 33 It is noteworthy that several studies have demonstrated that cells with low expression of MMR proteins may demonstrate therapeutic resistance even in the absence of MSI. 33, 34 The role of MMR in determining primary sensitivity to radiation and to nucleoside analogues like 5-FU and gemcitabine 35, 36 is more controversial.
An alternative mechanistic explanation for our findings relates to the role of MMR in maintaining genomic integrity. MMR-deficient cells exhibit genomic instability associated with increased rates of sporadic mutations, as demonstrated by increased rates of carcinogenesis but also more rapid development of secondary resistance to therapeutic agents, such as cisplatin, topotecan, gemcitabine and etoposide. 37 Furthermore, when exposed to mutagenic agents, MMR-deficient cells generate resistant variants more rapidly than MMR-intact cells. 38 Wang et al demonstrated a dose-response effect between MLH1 expression and the degree of genomic instability (as measured by somatic indels). 13 Hence, compared with MMRproficient cells, cells with MMR dysfunction may more rapidly develop resistance during adjuvant chemoradiation, facilitating disease recurrence.
A strength of the current study is that it was based on a large, prospectively gathered, multicenter clinical trial, representing a homogenous tumor population that, at the time of tissue collection, was treatment-naive. Another strength is the use of HistoRx AQUA technology, which has been established as objective, reproducible, and suitable for clinical practice. Blinding of the pathologic samples helped avoid bias. The 2 treatment groups were well balanced (Table 1) , and their characteristics were similar to those of the patients who did not have tissue samples available (Supporting Table 1 ; see online supporting information). A limitation of the study is that a genomic analysis of the samples was not performed. MSI was assumed to be very low based on previous studies 30, 39 ; however, the frequency of minor genetic changes (eg, indels) was not known. Furthermore, it is unknown which factors influence MLH1 protein expression (eg, promoter hypermethylation or allelic loss) within this population. Although we hypothesized that lower levels of MLH1 expression would be correlated with dysfunctional MMR, additional mechanistic studies are required. The current study was based on the use of archival specimens derived from a TMA that lacked normal tissue samples; consequently, we were unable to assess intratumoral heterogeneity of MLH1expression, and we could not compare tumor expression levels with those in normal (eg, pancreatic) tissues. We plan to perform such comparisons in future studies.
Although these current findings are in line with 2 smaller studies that have correlated MLH1 expression with outcomes in patients with pancreatic cancer, 14, 15 ideally, the results would be validated in a similar, large data set from an additional prospective clinical trial. These findings raise several questions: Is MLH1 expression a predictive or prognostic factor? Does MLH1 expression correlate with prognosis in other stages of pancreatic cancer (eg, metastatic or postresection not in those who do not receive radiation)? Is the profound effect of MLH1 expression on OS demonstrated here the result of MMR dysfunction-induced primary or secondary resistance? Based on the proposed mechanism that low MLH1 expression is associated with the rapid development of resistance, we may hypothesize that patients who have tumors with high MLH1 expression may especially benefit from aggressive adjuvant regimens, such as the chemoradiation used in RTOG 9704. Conversely, those who have tumors with low MLH1 expression and have a poor prognosis may be best served by receiving chemotherapy alone. Hence MLH1 should join the list of potential biomarkers (eg, impaired homologous recombination, molecular subtypes based on genomic analysis) to be considered for use in a personalized approach to pancreatic cancer treatment.
In conclusion, the current results suggest that patients who have resected pancreatic tumors with above-average MLH1 expression have a good prognosis in the context of adjuvant chemoradiation. Once validated, MLH1 expression may prove to be a useful stratification factor for future trials of DNA-damaging agents in pancreatic cancer and also potentially may predict which patients can benefit from an aggressive, multimodality approach.
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